NASDAQ:MEIPMEI Pharma Stock Price, Forecast & News

$3.38

+0.08 (+2.42 %)

(As of 05/29/2020 12:56 PM ET)

Add

Compare

Today's Range

$3.37

Now: $3.38▼

$3.82

50-Day Range

$1.51

MA: $2.61▼

$3.51

52-Week Range

$0.72

Now: $3.38▼

$3.77

Volume3.52 million shs

Average Volume1.47 million shs

Market Capitalization$358.28 million

P/E RatioN/A

Dividend YieldN/A

Beta1.86

MEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. It also has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
MEI Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $13.00, MEI Pharma has a potential upside of 281.2% from its current price of $3.41.
Amount of Analyst Coverage
MEI Pharma has only been the subject of 2 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
MEI Pharma has received 340 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
MEI Pharma has received 267 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
MEI Pharma has received 56.01% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote “Outperform” if you believe MEIP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
MEI Pharma does not currently pay a dividend.
Dividend Growth
MEI Pharma does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MEI Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.77% of the stock of MEI Pharma is held by insiders.
Percentage Held by Institutions
66.82% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for MEI Pharma are expected to decrease in the coming year, from ($0.06) to ($0.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MEI Pharma is -11.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MEI Pharma is -11.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MEI Pharma has a P/B Ratio of 4.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.46 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MEIP

Previous SymbolNASDAQ:MSHL

CUSIPN/A

CIK1262104

Webwww.meipharma.com

Phone858-369-7100

Debt

Debt-to-Equity RatioN/A

Current Ratio9.30

Quick Ratio9.30

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.91 million

Price / Sales72.97

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.70 per share

Price / Book4.83

Profitability

EPS (Most Recent Fiscal Year)($0.62)

Net Income$-16,820,000.00

Net Margins-539.48%

Return on Equity-60.32%

Return on Assets-41.93%

Miscellaneous

Employees32

Outstanding Shares106,000,000

Market Cap$358.28 million

Next Earnings Date8/26/2020 (Estimated)

OptionableOptionable

Receive MEIP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.

MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

How has MEI Pharma's stock been impacted by COVID-19 (Coronavirus)?

MEI Pharma's stock was trading at $1.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MEIP shares have increased by 120.0% and is now trading at $3.41. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MEI Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MEI Pharma.

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 26th 2020. View our earnings forecast for MEI Pharma.

How were MEI Pharma's earnings last quarter?

MEI Pharma Inc (NASDAQ:MEIP) released its quarterly earnings results on Thursday, May, 7th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.09. The firm had revenue of $1.24 million for the quarter, compared to the consensus estimate of $1.28 million. MEI Pharma had a negative net margin of 539.48% and a negative return on equity of 60.32%. View MEI Pharma's earnings history.

What price target have analysts set for MEIP?

3 brokerages have issued twelve-month target prices for MEI Pharma's stock. Their forecasts range from $10.00 to $16.00. On average, they anticipate MEI Pharma's share price to reach $13.00 in the next year. This suggests a possible upside of 281.2% from the stock's current price. View analysts' price targets for MEI Pharma.

Has MEI Pharma been receiving favorable news coverage?

Media headlines about MEIP stock have trended somewhat negative on Friday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MEI Pharma earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutMEI Pharma.

Who are some of MEI Pharma's key competitors?

Some companies that are related to MEI Pharma include Innoviva (INVA), Portola Pharmaceuticals (PTLA), Phoenix Tree (IMAB), Intra-Cellular Therapies (ITCI), Karyopharm Therapeutics (KPTI), Tricida (TCDA), Phathom Pharmaceuticals (PHAT), Supernus Pharmaceuticals (SUPN), Revance Therapeutics (RVNC), Arcus Biosciences (RCUS), Cytokinetics (CYTK), Kiniksa Pharmaceuticals (KNSA), I-Mab (ARQT), MacroGenics (MGNX) and Myovant Sciences (MYOV). View all competitors.

What other stocks do shareholders of MEI Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), SCYNEXIS (SCYX), Verastem (VSTM), Rigel Pharmaceuticals (RIGL), Opko Health (OPK), Actinium Pharmaceuticals (ATNM), Catalyst Pharmaceuticals (CPRX), Synergy Pharmaceuticals (SGYP) and TG Therapeutics (TGTX).

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the following people:

Dr. Daniel P. Gold, CEO, Pres & Director (Age 65)
Mr. Brian G. Drazba CPA, Sec. & CFO (Age 58)
Mr. David M. Urso Esq., J.D., COO, Sr. VP of Corp. Devel. & Gen. Counsel (Age 55)
Dr. Robert D. Mass M.D., Chief Medical Officer (Age 65)
Mr. David A. Walsey, VP of IR & Corp. Communications

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Vivo Capital LLC (9.23%), BlackRock Inc. (5.14%), Wasatch Advisors Inc. (4.78%), Perceptive Advisors LLC (2.86%), Perceptive Advisors LLC (2.86%) and Burrage Capital Management LLC (2.85%). Company insiders that own MEI Pharma stock include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, David M Urso and Thomas C Reynolds. View institutional ownership trends for MEI Pharma.

Which major investors are selling MEI Pharma stock?

MEIP stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Burrage Capital Management LLC, Morgan Stanley, ClariVest Asset Management LLC, JPMorgan Chase & Co., Parametric Portfolio Associates LLC, and WINTON GROUP Ltd. View insider buying and selling activity for MEI Pharma.

Which major investors are buying MEI Pharma stock?

MEIP stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Wasatch Advisors Inc., Geode Capital Management LLC, State Street Corp, Driehaus Capital Management LLC, Wells Fargo & Company MN, and Bank of New York Mellon Corp. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, and Thomas C Reynolds. View insider buying and selling activity for MEI Pharma.

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $3.41.

How big of a company is MEI Pharma?

MEI Pharma has a market capitalization of $361.46 million and generates $4.91 million in revenue each year. The company earns $-16,820,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.

What is MEI Pharma's official website?

The official website for MEI Pharma is www.meipharma.com.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 3611 VALLEY CENTER DRIVE, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff